ban on compounded semaglutide What's Happening with & Tirzepatide? Drugmakers battle pharmacies over compounded

Start low and go slow

Whether you plan to continue the medication long-term or eventually taper off, building sustainable habits during this phase is critical

Staying hydrated is key to preventing headache symptoms

Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications

Medical history review identifies potential contraindications

What follows is the most complete breakdown of BMI requirements for GLP-1 eligibility you will find anywhere